Adverse renal effects of check-point inhibitors (ICI) in cancer patients : Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology
Copyright © 2022 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved..
The most widely used approach in the immunotherapy treatment of cancer is the administration of monoclonal antibodies directed against regulatory molecules of immune control that inhibit the activation of T cells, the so-called check point inhibitors (ICI). ICI nephrotoxicity epidemiology and pathology; its diagnosis with or without kidney biopsy; the type and duration of treatment; the possibility of rechallenging after kidney damage; and its indication in patients with cancer and renal transplantation are certainly controversial. In the absence of definitive studies, this document is intended to specify some recommendations agreed by the group of Onconephrology experts of the Spanish Society of Nephrology in those areas related to ICI nephrotoxicity, in order to help decision-making in daily clinical practice in Onconephrology consultations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Nefrologia - 43(2023), 5 vom: 23. Sept., Seite 622-635 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alonso, Fabiola [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 31.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nefroe.2023.11.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364921994 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364921994 | ||
| 003 | DE-627 | ||
| 005 | 20240131231949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nefroe.2023.11.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1276.xml |
| 035 | |a (DE-627)NLM364921994 | ||
| 035 | |a (NLM)38000944 | ||
| 035 | |a (PII)S2013-2514(23)00170-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alonso, Fabiola |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adverse renal effects of check-point inhibitors (ICI) in cancer patients |b Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 31.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a The most widely used approach in the immunotherapy treatment of cancer is the administration of monoclonal antibodies directed against regulatory molecules of immune control that inhibit the activation of T cells, the so-called check point inhibitors (ICI). ICI nephrotoxicity epidemiology and pathology; its diagnosis with or without kidney biopsy; the type and duration of treatment; the possibility of rechallenging after kidney damage; and its indication in patients with cancer and renal transplantation are certainly controversial. In the absence of definitive studies, this document is intended to specify some recommendations agreed by the group of Onconephrology experts of the Spanish Society of Nephrology in those areas related to ICI nephrotoxicity, in order to help decision-making in daily clinical practice in Onconephrology consultations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute interstitial nephritis | |
| 650 | 4 | |a Acute kidney injury | |
| 650 | 4 | |a Efectos inmunes renales adversos | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Inhibidores del check-point | |
| 650 | 4 | |a Inmunoterapia | |
| 650 | 4 | |a Insuficiencia renal aguda | |
| 650 | 4 | |a Nefritis tubulointersticial aguda | |
| 650 | 4 | |a Renal immune-related adverse effect | |
| 650 | 4 | |a Renal transplantation | |
| 650 | 4 | |a Trasplante renal | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 700 | 1 | |a Martín de Francisco, Ángel L M |e verfasserin |4 aut | |
| 700 | 1 | |a Auñón, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a García-Carro, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a García, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Mcía, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Quintana, Luis F |e verfasserin |4 aut | |
| 700 | 1 | |a Quiroga, Borja |e verfasserin |4 aut | |
| 700 | 1 | |a Soler, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Torregrosa, Isidro |e verfasserin |4 aut | |
| 700 | 0 | |a Onconephrology Group of the Spanish Society of Nephrology |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nefrologia |d 2018 |g 43(2023), 5 vom: 23. Sept., Seite 622-635 |w (DE-627)NLM270991409 |x 2013-2514 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:5 |g day:23 |g month:09 |g pages:622-635 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nefroe.2023.11.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 5 |b 23 |c 09 |h 622-635 | ||